Andres Y. Maldonado
Stock Analyst at HC Wainwright & Co.
(4.88)
# 61
Out of 5,147 analysts
42
Total ratings
65.85%
Success rate
73.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andres Y. Maldonado
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Buy | $75 → $80 | $58.80 | +36.05% | 5 | Feb 27, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $25 → $22 | $10.60 | +107.55% | 2 | Feb 25, 2026 | |
| IBRX ImmunityBio | Maintains: Buy | $10 → $15 | $9.78 | +53.37% | 9 | Feb 23, 2026 | |
| IMNM Immunome | Initiates: Buy | $40 | $21.86 | +82.98% | 1 | Feb 12, 2026 | |
| TARA Protara Therapeutics | Reiterates: Buy | $23 | $6.36 | +261.64% | 3 | Feb 10, 2026 | |
| NBP NovaBridge Biosciences | Maintains: Buy | $7 → $9 | $3.28 | +174.39% | 1 | Feb 6, 2026 | |
| VSTM Verastem | Assumes: Buy | $18 | $5.72 | +214.69% | 1 | Feb 4, 2026 | |
| ERAS Erasca | Maintains: Buy | $11 → $15 | $13.66 | +9.81% | 2 | Jan 26, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $44 → $58 | $44.27 | +31.01% | 2 | Jan 26, 2026 | |
| STRO Sutro Biopharma | Maintains: Neutral | $2 → $10 | $20.47 | -51.15% | 1 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $4 | $0.60 | +566.44% | 1 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $60 | $42.12 | +42.45% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $1.06 | +560.38% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $21.71 | +84.25% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $8.57 | +366.74% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $5.25 | +338.10% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $105 | $54.81 | +91.59% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $10.11 | +147.28% | 2 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $5.89 | +273.51% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $20 | $14.19 | +40.94% | 1 | Aug 8, 2025 |
CG Oncology
Feb 27, 2026
Maintains: Buy
Price Target: $75 → $80
Current: $58.80
Upside: +36.05%
Day One Biopharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $25 → $22
Current: $10.60
Upside: +107.55%
ImmunityBio
Feb 23, 2026
Maintains: Buy
Price Target: $10 → $15
Current: $9.78
Upside: +53.37%
Immunome
Feb 12, 2026
Initiates: Buy
Price Target: $40
Current: $21.86
Upside: +82.98%
Protara Therapeutics
Feb 10, 2026
Reiterates: Buy
Price Target: $23
Current: $6.36
Upside: +261.64%
NovaBridge Biosciences
Feb 6, 2026
Maintains: Buy
Price Target: $7 → $9
Current: $3.28
Upside: +174.39%
Verastem
Feb 4, 2026
Assumes: Buy
Price Target: $18
Current: $5.72
Upside: +214.69%
Erasca
Jan 26, 2026
Maintains: Buy
Price Target: $11 → $15
Current: $13.66
Upside: +9.81%
Scholar Rock Holding
Jan 26, 2026
Maintains: Buy
Price Target: $44 → $58
Current: $44.27
Upside: +31.01%
Sutro Biopharma
Dec 22, 2025
Maintains: Neutral
Price Target: $2 → $10
Current: $20.47
Upside: -51.15%
Dec 19, 2025
Maintains: Buy
Price Target: $10 → $4
Current: $0.60
Upside: +566.44%
Dec 9, 2025
Maintains: Buy
Price Target: $20 → $60
Current: $42.12
Upside: +42.45%
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.06
Upside: +560.38%
Oct 27, 2025
Reiterates: Buy
Price Target: $40
Current: $21.71
Upside: +84.25%
Oct 20, 2025
Reiterates: Buy
Price Target: $40
Current: $8.57
Upside: +366.74%
Sep 29, 2025
Reiterates: Buy
Price Target: $23
Current: $5.25
Upside: +338.10%
Sep 29, 2025
Maintains: Buy
Price Target: $70 → $105
Current: $54.81
Upside: +91.59%
Sep 12, 2025
Reiterates: Buy
Price Target: $25
Current: $10.11
Upside: +147.28%
Aug 13, 2025
Reiterates: Buy
Price Target: $22
Current: $5.89
Upside: +273.51%
Aug 8, 2025
Maintains: Buy
Price Target: $25 → $20
Current: $14.19
Upside: +40.94%